Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...
Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance
Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...
Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke
Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...
Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia
Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...
Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...
Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...
HHS Implements Trump’s Order for Most-Favored-Nation Drug Pricing
The U.S. Department of Health and Human Services (HHS) announced that it is taking immediate...
Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study
China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...
AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...
AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion
UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...
Pulnovo Medical Raises Tens of Millions in New Financing Round
Wuxi-based Pulnovo Medical Limited, a developer of medical devices for hypertension and heart failure, announced...
PHASE Scientific Completes Series A Financing to Advance Urine-Based Diagnostics
Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series...
China’s CDE Announces 94th Batch of Reference Preparations for Generic Evaluation
China’s Center for Drug Evaluation (CDE) has selected the 94th batch of reference preparations for...
Merck KGaA Partners with IMEC to Develop Advanced Microphysiological Systems Platform
German major Merck KGaA (ETR: MRK) this week announced a partnership with Belgium-based Interuniversity Microelectronics Centre...
Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors
China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...
China’s County Hospitals Show Improved Medical Service Capability in 2024
The National Health Commission (NHC) released a notice reporting the status of the county hospital...
3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC
China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...
Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...
Yifan Pharma Licenses Ryzneuta to Lenis for Balkan Markets
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced a licensing agreement with Lenis, a Slovenian-based...
Abbisko’s Pimitinib Granted Priority Review for TGCT Treatment in China
Abbisko Therapeutics Co., Ltd (HKG: 2256) announced that its self-developed, highly selective small-molecule CSF-1R inhibitor,...